Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
ARC Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Blood. 2023 Oct 5;142(14):1233-1242. doi: 10.1182/blood.2023020441.
Human 12-lipoxygenase (12-LOX) is a key enzyme involved in platelet activation, and the regulation of its activity has been targeted for the treatment of heparin-induced thrombocytopenia. Despite the clinical importance of 12-LOX, the exact mechanisms by which it affects platelet activation are not fully understood, and the lack of structural information has limited drug discovery efforts. In this study, we used single-particle cryo-electron microscopy to determine high-resolution structures (1.7-2.8 Å) of human 12-LOX. Our results showed that 12-LOX can exist in multiple oligomeric states, from monomer to hexamer, which may affect its catalytic activity and membrane association. We also identified different conformations within the 12-LOX dimer, which likely represent different time points in its catalytic cycle. Furthermore, we identified small molecules bound to 12-LOX. The active site of the 12-LOX tetramer was occupied by an endogenous 12-LOX inhibitor, a long-chain acyl coenzyme A. In addition, we found that the 12-LOX hexamer can simultaneously bind to arachidonic acid and ML355, a selective 12-LOX inhibitor that has passed a phase 1 clinical trial for the treatment of heparin-induced thrombocytopenia and received a fast-track designation by the Food and Drug Administration. Overall, our findings provide novel insights into the assembly of 12-LOX oligomers, their catalytic mechanism, and small molecule binding, paving the way for further drug development targeting the 12-LOX enzyme.
人 12-脂氧合酶(12-LOX)是参与血小板激活的关键酶,其活性的调节已成为肝素诱导的血小板减少症治疗的靶点。尽管 12-LOX 具有重要的临床意义,但它影响血小板激活的确切机制尚未完全阐明,而且缺乏结构信息限制了药物发现的努力。在这项研究中,我们使用单颗粒冷冻电子显微镜确定了人 12-LOX 的高分辨率结构(1.7-2.8Å)。我们的结果表明,12-LOX 可以存在于多种寡聚状态,从单体到六聚体,这可能会影响其催化活性和膜结合。我们还在 12-LOX 二聚体中鉴定了不同的构象,这些构象可能代表其催化循环的不同时间点。此外,我们还鉴定了与 12-LOX 结合的小分子。12-LOX 四聚体的活性部位被一种内源性 12-LOX 抑制剂,长链酰基辅酶 A 占据。此外,我们发现 12-LOX 六聚体可以同时结合花生四烯酸和 ML355,ML355 是一种选择性 12-LOX 抑制剂,已通过治疗肝素诱导的血小板减少症的 1 期临床试验,并获得美国食品和药物管理局的快速通道指定。总的来说,我们的研究结果为 12-LOX 寡聚体的组装、其催化机制和小分子结合提供了新的见解,为进一步开发针对 12-LOX 酶的药物铺平了道路。